Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents

Fundamental and Clinical Pharmacology

Volumn 23, Issue 1, 2009, Pages 1-9

  Husted, Steen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ACS; New drugs; Platelet ADP receptors

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; KETOCONAZOLE; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR;

ADD ON THERAPY; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DYSPNEA; HEART INFARCTION; HUMAN; ISCHEMIA; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; ADENOSINE; ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; HUMANS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 61349172986     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00660.x     Document Type: Review

References (69)

1. CAPRIE Steering Committee. A randomized blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet (1996) 348 1329 1339.
2. Mehta S.R., Yusuf S., Peters R.J. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet (2001) 358 527 533.
3. Yusuf S., Zhao F., Mehta S.R. et al. Clopidogrel in unstable angina to prevent recurrent events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345 494 502.
4. Steinhubl S.R., Berger P.B., Mann J.T. III. et al. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA (2002) 288 2411 2420.
5. Chen Z.M., Jiang L.X., Chen Y.P. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised, placebo-controlled trial. Lancet (2005) 366 1607 1621.
6. Sabatine M.S., Cannon C.P., Gibson C.M. et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA (2005) 294 1224 1232.
7. Sabatine M.S., Cannon C.P., Gibson C.M. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. (2005) 352 1179 1189.
8. Muller C., Buttner H.J., Petersen J., Roskamm H. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation (2000) 101 590 593.
9. Braunwald E., Antman E.M., Beasley J.W. et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol. (2002) 40 1366 1374.
10. Brandt J.T., Payne C.D., Wiviott S.D. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. (2007) 153 66.e9 66.e16.
11. Steinhubl S.R., Berger P.B., Brennan D.M. et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J. Am. Coll. Cardiol. (2006) 47 939 943.
12. Gurbel P.A., Bliden K.P. Durability of platelet inhibition by clopidogrel. Am. J. Cardiol. (2003) 91 1123 1125.
13. Müller I., Besta F., Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb. Haemost. (2003) 89 783 787.
14. Serebruany V.L., Steinhubl S.R., Berger P.B. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. (2005) 45 246 251.
15. Heptinstall S. Variable therapeutic effectiveness of clopidogrel in acute coronary syndromes. J. Thromb. Haemost. (2006) 4 539 541.
16. Geisler T., Langer H., Wydymus M. et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur. Heart J. (2006) 27 2420 2425.
17. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. (2007) 49 1505 1516.
18. Barragan P., Bouvier J.L., Roquebert P.O. et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. (2003) 59 295 302.
19. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107 2908 2913.
20. Matetzky S., Shenkman B., Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 109 3171 3175.
21. Wiviott S.D., Antman E.M. Clopidogrel resistance: a new chapter in a fast moving story. Circulation (2004) 109 3064 3067.
22. Ajzenberg N., Aubry P., Huisse M.G. et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis. A case-control study. J. Am. Coll. Cardiol. (2005) 45 1753 1756.
23. Gurbel P.A., Bliden K.P., Hayes K.M. et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. (2005) 45 1392 1396.
24. Cuisset T., Frere C., Quilici J. et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. (2006) 48 1339 1345.
25. Cuisset T., Frere C., Quilici J. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. (2006) 4 542 549.
26. Hochholzer W., Trenk D., Bestehorn H.P. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. (2006) 48 1742 1750.
27. Lev E.I., Patel R.T., Maresh K.J. et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention. The role of dual drug resistance. J. Am. Coll. Cardiol. (2006) 47 27 33.
28. Michos E.D., Ardehali R., Blumenthal R.S., Lange R.A., Ardehali H. Aspirin and clopidogrel resistance. Mayo Clin. Proc. (2006) 81 518 526.
29. Bliden K.P., DiChiara J., Tantry U.S. et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. Is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. (2007) 49 657 666.
30. Buonamici P., Marcucci R., Migliorini A. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. (2007) 49 2312 2317.
31. Lau W.C., Gurbel P.A., Watkins P.B. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation (2004) 109 166 171.
32. Farid N.A., Payne C.D., Small D.S. et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther. (2007) 81 735 741.
33. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E. et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol. (2006) 26 1895 1900.
34. Hulot J.S., Bura A., Villard E. et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood (2006) 108 2244 2247.
35. Montalescot G., Sideris G., Meuleman C. et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol. (2006) 48 931 938.
36. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation (2006) 114 774 782.
37. Karabulut H., Toramon F., Evrenkaya S. et al. Clopidogrel does not increase bleeding and allogeneic blood transfusion in coronary artery surgery. Eur. J. Cardiothorac. Surg. (2004) 25 419 423.
38. Carpino P.A., Bojar R.M., Khabbaz K.R. et al. Clopidogrel therapy prior to coronary artery bypass surgery does not increase bleeding complications or use of blood products. Crit. Care Med. (2001) 29 (Suppl) 314.
39. Yende S., Wunderink R.G. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit. Care Med. (2001) 29 2271 2275.
40. Hongo R.H., Ley J., Dick S.E. et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J. Am. Coll. Cardiol. (2002) 40 231 237.
41. Gansera B., Schmidtler F., Spiliopoulos K., Angelis I., Neumaier-Prauser P., Kemkes B.M. Urgent or emergent coronary revascularization using bilateral internal thoracic artery after previous clopidogrel antiplatelet therapy. Thorac. Cardiovasc. Surg. (2003) 51 185 189.
42. Ray J.G., Deniz S., Olivieri A. et al. Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel. BMC. Cardiovasc. Disord. (2003) 3 3 8.
43. Chu M.W., Wilson S.R., Novick R.J. et al. Does clopidogrel increase blood loss following coronary artery bypass surgery? Ann. Thorac. Surg. (2004) 78 1536 1541.
44. Englberger L., Faeh B., Berdat P.A. et al. Impact of clopidogrel in coronary artery bypass grafting. Eur. J. Cardiothorac. Surg. (2004) 26 96 101.
45. Fox K.A.A., Mehta S.R., Peters R. et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation (2004) 110 1202 1208.
46. Kapetanakis E.I., Medlam D.A., Boyce S.W. et al. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache? Eur. Heart J. (2005) 26 576 583.
47. Mehta R.H., Roe M.T., Mulgund J. et al. Acute clopidogrel use and outcomes in patients with non-ST-segment elevation acute coronary syndromes undergoing coronary artery bypass surgery. J. Am. Coll. Cardiol. (2006) 48 281 286.
48. Purkayastha S., Athanasiou T., Malinovski V. et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart (2006) 92 531 532.
49. Picker S.M., Kaleta T., Hekmat K. et al. Antiplatelet therapy preceding coronary artery surgery: implications for bleeding, transfusion requirements and outcome. Eur. J. Anaesthesiol. (2007) 24 332 339.
50. Kang W., Theman T.E., Reed J.F. III. et al. The effect of preoperative clopidogrel on bleeding after coronary artery bypass surgery. J. Surg. Educ. (2007) 64 88 92.
51. Chen L., Bracey A.W., Radovancevic R. Clopidogrel and bleeding in patients undergoing elective coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg. (2004) 128 425 431.
52. Akowuah E., Shrivastava V., Jamnadas B. et al. Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. Ann. Thorac. Surg. (2005) 80 149 152.
53. van der Linden J., Lindvall G., Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery. A double-blind, placebo-controlled, randomized clinical trial. Circulation (2005) 112 (Suppl. 1) I-276 I-280.
54. Ouattara A., Bouzguenda H., Le Manach Y. et al. Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low dose of aprotinin. Eur. Heart J. (2007) 28 1025 1032.
55. Vilahur G., Choi B.G., Zafar M.U. et al. Normalization of platelet reactivity in clopidogrel-treated patients. J. Thromb. Haemost. (2007) 5 82 90.
56. U.S. Food and Drug Administration. 2007 Safety Information Alerts. Trasylol (Aprotinin Injection). Available at: http://www.fda.gov/medwatch/ safety/2007/safety07.htm#Trasylol (accessed on 29 April 2008).
57. Bayer Healthcare. Important Trasylol® Safety Information. Available at: http://www.bayerhealthcare.com/scripts/pages/en/press/information-on- trasylol/trasylol-safety-information-05-11/index.php (accessed on 30 April 2008).
58. Pretorius R., BART Investigators. Major outcomes following high-risk cardiac surgery. Can. J. Anaesth. (2006) 53 (Suppl. 1) 26231.
59. 12 receptor antagonist activity. Semin. Thromb. Hemost. (2005) 31 184 194.
60. 12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial. Circulation (2005) 111 3366 3373.
61. Jernberg T., Payne C.D., Winters K.J. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. (2006) 27 1166 1173.
62. Wiviott S.D., Braunwald E., McCabe C.H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. (2007) 357 2001 2015.
63. Anderson J.L., Adams C.D., Antman E.M. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol. (2007) 50 e1 e157.
64. Antman E.M., Hand M., Armstrong P.W. et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation (2008) 117 296 329.
65. Peters G., Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD6140 - an oral reversible ADP receptor antagonist. Haematologica (2004) 989 (Suppl. 7) 14. Abstract.
66. 12 antagonists. Semin. Thromb. Hemost. (2005) 31 195 204.
67. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. (2006) 27 1038 1047.
68. Cannon C.P., Husted S., Harrington R.A. et al., for the DISPERSE2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE2 trial. J. Am. Coll. Cardiol. (2007) 50 1844 1851.
69. 12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. (2007) 50 1852 1856.